肝硬化与骨代谢障碍

doi:10.3969/j.issn.1672-5069.2017.04.002

Abstract

Xiong Ji, Wen Liangzhi, Sun Wenjing, et al.. Disorders of bone metabolism in patients with chronic liver disease[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(4): 388-390.

[1] Gasser RW. Cholestasis and metabolic bone disease-a clinical review. Wien Med Wochenschr,2008,158（19-20）:553-557.
[2] Raszeja-Wyszomirska J,Miazgowski T. Osteoporosis in primary biliary cirrhosis of the liver. Prz Gastroenterol,2014,9（2）: 82-87.
[3] Gonzalez-Calvin JL,Gallego-Rojo F,Fernandez-Perez R,et al. Osteoporosis,mineral metabolism,and serum soluble tumor necrosis factor receptor p55 in viral cirrhosis. J Clin Endocrinol Metab,2004,89（9）:4325-4330.
[4] Goubraim R,Kabbaj N,Salihoun M,et al. Metabolic bone disease in viral cirrhosis:A prospective study. ISRN Hepatol,2013,2013: 276563.
[5] Wariaghli G, Allali F, El Maghraoui A, et al. Osteoporosis in patients with primary biliary cirrhosis. Eur J Gastroenterol Hepatol, 2010,22（12）: 1397-1401.
[6] Guichelaar MM,Malinchoc M,Sibonga J,et al. Bone metabolism in advanced cholestatic liver disease:analysis by bone histomorphometry. Hepatology, 2002,36（4 Pt 1）: 895-903.
[7] Miroliaee A,Nasiri-Toosi M,Khalilzadeh O,et al. Disturbances of parathyroid hormone-vitamin D axis in non-cholestatic chronic liver disease:a cross-sectional study. Hepatol Int,2010,4（3）:634-640.
[8] Luxon BA. Bone disorders in chronic liver diseases. Curr Gastroenterol Rep,2011,13（1）:40-48.
[9] Nakchbandi IA. Osteoporosis and fractures in liver disease: relevance,pathogenesis and therapeutic implications. World J Gastroenterol,2014,20（28）:9427-9438.
[10] Strandberg L,Lorentzon M,Hellqvist A,et al. Interleukin-1 system gene polymorphisms are associated with fat mass in young men. J Clin Endocrinol Metab,2006,91（7）:2749-2754.
[11] Ye XL,Lu CF. Association of polymorphisms in the leptin and leptin receptor genes with inflammatory mediators in patients with osteoporosis. Endocrine,2013,44（2）:481-488.
[12] Vermeer C. Vitamin K:the effect on health beyond coagulation -an overview. Food Nutr Res,2012,56:321-325..
[13] Garcia-Valdecasas-Campelo E,Gonzalez-Reimers E,Santolaria-
Fernandez F,et al. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease. Alcohol Alcohol,2006,41（3）: 261-266.
[14] Walsh MC,Choi Y. Biology of the RANKL-RANK-OPG system in immunity,bone,and beyond. Front Immunol,2014,5:511.
[15] Lleo A,Bian Z,Zhang H,et al. Quantitation of the Rank-Rankl axis in primary biliary cholangitis. PLoS One,2016,11（9）:e0159612.
[16] Wu Q,Zhou X,Huang D,et al. IL-6 Enhances osteocyte-mediated osteoclastogenesis by promoting JAK2 and RANKL activity in vitro. Cell Physiol Biochem,2017,41（4）: 1360-1369.
[17] 高学松,段雪飞. 肝硬化合并肝性骨病的研究进展. 中国肝脏病杂志,2015,7（4）: 14-18.
[18] Oei L,Koromani F,Rivadeneira F,et al. Quantitative imaging methods in osteoporosis. Quant Imaging Med Surg,2016,6（6）: 680-698.
[19] Engelke K,Libanati C,Liu Y,et al. Quantitative computed tomography （QCT） of the forearm using general purpose spiral whole-body CT scanners:accuracy,precision and comparison with dual-energy X-ray absorptiometry （DXA）. Bone,2009,45（1）:110-118.
[20] 李康军,王小英, 任志. 肝硬化患者腰椎骨密度CT定量评价. 医学信息,2011,9: 4317.
[21] Santos LA,Romeiro FG. Diagnosis and management of cirrhosis-related osteoporosis. 2016,2016: 1423462.
[22] Levy C,Harnois DM, Angulo P,et al. Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study. Liver Int,2005,25（1）:117-121.

Disorders of bone metabolism in patients with chronic liver disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[3]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[4]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.
[5]	Wang Yueyuan, Wang Yan, Zhang Dandan. Short-term efficacy of terlipressin and octreotide combination in treatment of cirrhotic patients complicated by hepatorenal syndrome [J]. Journal of Practical Hepatology, 2019, 22(5): 684-687.
[6]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[7]	Dan Zhuyongji, Liu Zhilan, Lu Yanyan, et al. Efficacy of endoscopic sequential variceal 1igation plus sclerotherapy in treatment of patients with hepatitis B-induced liver cirrhosis complicated by esophageal gastric varices bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 692-695.
[8]	Huang Hanjun, Lu Fengrong, Zhang Can. Clinical value of MRI scanning based on exchange hemodynamics model in evaluating liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 696-699.
[9]	Zhao Fangfang, Zhai Yongzhen, Feng Guohe. Efficacy and safety of autologous peripheral blood stem cell transplantation in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 700-703.
[10]	Chen Shan, Zhuang Huashuai, Xing Yixi, et al. Preventive application of meropenem in patients with liver cirrhosis complicated by upper gastrointestinal bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 704-707.
[11]	Xu Qilin, Hao Shaohuan, Ran Bo. Risk factors of portal vein thrombosis after splenectomy in patients with liver cirrhosis and portal hypertension [J]. Journal of Practical Hepatology, 2019, 22(5): 708-711.
[12]	Jin Lianghong, Li Xingjie, Guan Hongbo, et al. Clinical value of dual-energy CT iodine quantification combined with dynamic contrast-enhanced MRI in evaluating hepatic hemodynamics and liver functions in patients with hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 712-715.
[13]	Bian Xinqu, Chen Jie, Liu Yanmin, et al. Serum thyroid hormone level changes in patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy [J]. Journal of Practical Hepatology, 2019, 22(5): 716-719.
[14]	Xiao Han, Wang Li. Mechanisms of thrombocytopenia in liver cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 462-465.
[15]	Han Meiling, Chen Ping. Antiviral therapy in patients with liver cirrhosis and thrombocytopenia [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 466-469.